RU2018135550A - Связывающие ilt7 молекулы и способы их применения - Google Patents
Связывающие ilt7 молекулы и способы их применения Download PDFInfo
- Publication number
- RU2018135550A RU2018135550A RU2018135550A RU2018135550A RU2018135550A RU 2018135550 A RU2018135550 A RU 2018135550A RU 2018135550 A RU2018135550 A RU 2018135550A RU 2018135550 A RU2018135550 A RU 2018135550A RU 2018135550 A RU2018135550 A RU 2018135550A
- Authority
- RU
- Russia
- Prior art keywords
- binding protein
- ilt7
- host cell
- isolated
- antibody
- Prior art date
Links
- 101000984199 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 4 Proteins 0.000 title claims 17
- 102100025555 Leukocyte immunoglobulin-like receptor subfamily A member 4 Human genes 0.000 title claims 17
- 238000000034 method Methods 0.000 title claims 5
- 210000004027 cell Anatomy 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102000023732 binding proteins Human genes 0.000 claims 5
- 108091008324 binding proteins Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 4
- 201000002481 Myositis Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010001367 Adrenal insufficiency Diseases 0.000 claims 1
- 206010062746 Carditis Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 208000021646 inflammation of heart layer Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Rehabilitation Therapy (AREA)
- Transplantation (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
Claims (19)
1. Выделенный связывающий ILT7 белок, который может связываться с тем же эпитопом ILT7, что и антитело, содержащее вариабельную область тяжелой цепи (VH) SEQ ID NO:202 и вариабельную область легкой цепи (VL) SEQ ID NO:207.
2. Выделенный связывающий ILT7 белок, содержащий определяющие комплементарность области (CDR) HCDR1, HDR2, HCDR3, LCDR1, LCDR2 и LCDR3, содержащие последовательности SEQ ID NO: 203, 204, 205, 208, 209 и 210, соответственно.
3. Выделенный связывающий ILT7 белок по п. 1, где связывающий ILT7 белок содержит VH по меньшей мере на 85%, 90%, 95%, 96%, 97%, 98% или 99% идентичную SEQ ID NO:202 и/или VL по меньшей мере на 85%, 90%, 95%, 96%, 97%, 98% или 99% идентичную SEQ ID NO:207.
4. Выделенная связывающай ILT7 белок по любому из предшествующих пунктов, который содержит антитело или его антигенсвязывающий фрагмент, где необязательно антитело или его антигенсвязывающий фрагмент являются афукозилированными.
5. Выделенный связывающий ILT7 белок по любому из предшествующих пунктов, где связывающий белок связывается с ILT7 человека и яванского макака.
6. Выделенный связывающий ILT7 белок по любому из предшествующих пунктов, где связывающий белок подавляет высвобождение интерферона (IFN) альфа мононуклеарными клетками периферической крови (PBMC) и/или обладает ADCC активностью по отношению к плазмацитоидным дендритным клеткам (pDC) в PMBC.
7. Выделенный связывающий ILT7 белок по любому из предшествующих пунктов, который содержит антитело мыши, антитело человека, химерное, гуманизированное антитело или антитело с измененной поверхностью или его антигенсвязывающий фрагмент.
8. Выделенный связывающий ILT7 белок по любому из предшествующих пунктов, который содержит моноклональное антитело или его антигенсвязывающий фрагмент.
9. Выделенный связывающий ILT7 белок по любому из предшествующих пунктов, где связывающий белок содержит константный домен IgG1 человека и константный домен лямбда-цепи человека.
10. Полинуклеотид, кодирующий связывающий ILT7 белок по любому из предшествующих пунктов.
11. Вектор, содержащий полинуклеотид по п. 10.
12. Клетка-хозяин, содержащая полинуклеотид по п. 10 или вектор по п. 11.
13. Клетка-хозяин по п. 12, где клетка-хозяин представляет собой клетку-хозяина млекопитающего.
14. Клетка-хозяин по п. 12 или 13, где клетка-хозяин не содержит фермент α-1,6-фукозилтрансферазу.
15. Способ получения связывающего белка против ILT7, включающий культивирование клетки-хозяина по любому из пп. 12-14 и выделение указанного связывающего белка.
16. Фармацевтическая композиция, содержащая (a) связывающий ILT7 белок по любому из пп. 1-9, полинуклеотид по п. 10, вектор по п. 11 или клетку-хозяина по любому из пп. 12-14 и (b) носитель.
17. Способ уменьшения высвобождения IFN-альфа плазмацитоидной дендритной клеткой, включающий приведение плазмацитоидной дендритной клетки в контакт со связывающим ILT7 белком по любому из пп. 1-9, полинуклеотидом по п. 10, вектором по п. 11, клеткой-хозяином по любому из пп. 12-14 или композицией по п. 16.
18. Способ лечения или профилактики аутоиммунного заболевания у являющегося человеком индивидуума, включающий введение индивидууму эффективного количества связывающего ILT7 белка по любому из пп. 1-9, полинуклеотида по п. 10, вектора по п. 11, клетки-хозяина по любому из пп. 12-14 или композиции по п. 16.
19. Способ по п. 18, где указанное аутоиммунное заболевание выбрано из группы, состоящей из миозита, диабета, болезни Хашимото, аутоиммунной надпочечниковой недостаточности, эритроцитарной анемии, рассеянного склероза, ревматоидного кардита, системной красной волчанки, псориаза, ревматоидного артрита, хронического воспаления, синдрома Шегрена, полимиозита, дерматомиозита, миозита с тельцами включения, юношеского миозита и склеродермии.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306125P | 2016-03-10 | 2016-03-10 | |
| US62/306,125 | 2016-03-10 | ||
| PCT/US2017/021616 WO2017156298A1 (en) | 2016-03-10 | 2017-03-09 | Ilt7 binding molecules and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018135550A true RU2018135550A (ru) | 2020-04-10 |
| RU2018135550A3 RU2018135550A3 (ru) | 2020-07-23 |
| RU2756109C2 RU2756109C2 (ru) | 2021-09-28 |
Family
ID=59790876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018135550A RU2756109C2 (ru) | 2016-03-10 | 2017-03-09 | Связывающие ilt7 молекулы и способы их применения |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11072652B2 (ru) |
| EP (1) | EP3426298A4 (ru) |
| JP (3) | JP6979976B2 (ru) |
| KR (4) | KR102632796B1 (ru) |
| CN (2) | CN109414499B (ru) |
| AR (2) | AR109450A1 (ru) |
| AU (2) | AU2017231833B2 (ru) |
| BR (1) | BR112018067951A2 (ru) |
| CA (1) | CA3017197A1 (ru) |
| IL (1) | IL261653A (ru) |
| MX (2) | MX2018010771A (ru) |
| RU (1) | RU2756109C2 (ru) |
| SG (2) | SG11201807523PA (ru) |
| TW (1) | TWI755380B (ru) |
| UA (1) | UA127731C2 (ru) |
| WO (1) | WO2017156298A1 (ru) |
| ZA (1) | ZA201806597B (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018010771A (es) | 2016-03-10 | 2019-05-15 | Viela Bio Inc | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. |
| EP3559042A4 (en) * | 2016-12-22 | 2020-11-25 | Icahn School of Medicine at Mount Sinai | ANTI-LILRB3 ANTIBODIES AND METHOD OF USING THEREOF |
| KR20220002888A (ko) * | 2019-04-19 | 2022-01-07 | 알로젠 테라퓨틱스 인코포레이티드 | 4g7-유래 키메라 항원 수용체에 대한 항체 |
| EP4069288A4 (en) * | 2019-12-06 | 2024-01-17 | Viela Bio, Inc. | TREATMENT METHODS USING ILT7 BINDING PROTEINS |
| KR20220119430A (ko) * | 2019-12-20 | 2022-08-29 | 메디뮨 엘엘씨 | 글리피칸 3을 표적으로 하는 키메라 항원 수용체로 암을 치료하는 조성물 및 방법 |
| WO2021203013A2 (en) * | 2020-04-03 | 2021-10-07 | Viela Bio, Inc. | Methods of treating immune mediated pulmonary injury |
| KR20240004451A (ko) | 2021-05-04 | 2024-01-11 | 비엘라 바이오, 인크. | Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법 |
| WO2024026388A1 (en) | 2022-07-27 | 2024-02-01 | Viela Bio, Inc. | Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein |
| WO2024126431A1 (en) | 2022-12-12 | 2024-06-20 | Horizon Therapeutics Ireland Dac | Anti-ilt7 binding agents for the treatment and prevention of myositis |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2096948A (en) | 1935-12-20 | 1937-10-26 | Anchor Steel & Conveyor Co | Conveyer system |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| ATE243745T1 (de) | 1994-01-31 | 2003-07-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| DE4440354A1 (de) | 1994-11-11 | 1996-05-15 | Hoechst Schering Agrevo Gmbh | Kombinationen aus Phenylsulfonylharnstoff-Herbiziden und Safenern |
| JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質／（ポリ）ペプチドライブラリー |
| US6706484B1 (en) | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2339889C (en) | 1999-07-02 | 2012-01-31 | Morphosys Ag | Identification of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| AU2001236807A1 (en) | 2000-02-10 | 2001-08-20 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| US6897067B2 (en) | 2000-11-03 | 2005-05-24 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
| AU2001297872B2 (en) | 2000-11-17 | 2006-11-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| AU2002318944A1 (en) * | 2001-08-01 | 2003-02-17 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA3077873A1 (en) | 2002-03-20 | 2003-10-02 | Catalina Marketing Corporation | Targeted incentives based upon predicted behavior |
| KR101086533B1 (ko) | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
| AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| EP1647596A4 (en) | 2003-07-18 | 2008-02-13 | Mochida Pharm Co Ltd | MONOCLONAL ANTIBODY AGAINST GLYCOPROTEIN VI THE BLOOD PLATE MEMBRANE |
| US9208495B2 (en) | 2003-10-06 | 2015-12-08 | Yellowpages.Com Llc | Methods and apparatuses for advertisement presentation |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CN101155831B (zh) * | 2005-02-10 | 2015-08-19 | 贝勒研究院 | 抗干扰素α单克隆抗体及其使用方法 |
| WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| AU2012244391B2 (en) * | 2005-12-20 | 2014-09-11 | Sbi Biotech Co., Ltd. | Anti-ILT7 antibody |
| RS52860B (en) | 2005-12-20 | 2013-12-31 | Sbi Biotech Co. Ltd. | ANTI-ILT7 ANTITELO |
| WO2007118214A2 (en) * | 2006-04-07 | 2007-10-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Antibody compositions and methods for treatment of neoplastic disease |
| US7993648B2 (en) | 2006-05-03 | 2011-08-09 | The Regents of the Universitry of Colorado | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody |
| US7781306B2 (en) | 2007-06-20 | 2010-08-24 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor substrate and method for manufacturing the same |
| WO2010065536A2 (en) | 2008-12-01 | 2010-06-10 | The Board Of Regents Of The University Of Texas System | Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases |
| RS55641B1 (sr) | 2009-09-03 | 2017-06-30 | Medimmune Llc | Dijagnostičko sredstvo interferon tipa 1 |
| US20120316071A1 (en) * | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
| JP6211513B2 (ja) | 2011-04-26 | 2017-10-11 | ジェネンテック， インコーポレイテッド | 自己免疫疾患の治療のための組成物及び方法 |
| EP3421592B1 (en) | 2011-04-28 | 2023-09-13 | The Board of Trustees of the Leland Stanford Junior University | Identification of polynucleotides associated with a sample |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| HUE054362T2 (hu) * | 2012-01-31 | 2021-09-28 | Sbi Biotech Co Ltd | Foszfolipáz D4 elleni antitest |
| US8605807B1 (en) | 2012-05-22 | 2013-12-10 | Nigel Iain Stuart Macrae | Communicating distinct data over a single frequency using multiple linear polarized signals |
| CN104884049A (zh) * | 2012-11-08 | 2015-09-02 | 克莱尔塞德生物医学股份有限公司 | 用于在人类受试者中治疗眼部疾病的方法和装置 |
| US9114438B2 (en) | 2013-05-21 | 2015-08-25 | Applied Materials, Inc. | Copper residue chamber clean |
| CA2959165A1 (en) * | 2014-08-29 | 2016-03-03 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind oprf and opri |
| MX2018010771A (es) | 2016-03-10 | 2019-05-15 | Viela Bio Inc | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. |
| EP4069288A4 (en) | 2019-12-06 | 2024-01-17 | Viela Bio, Inc. | TREATMENT METHODS USING ILT7 BINDING PROTEINS |
| KR20240004451A (ko) | 2021-05-04 | 2024-01-11 | 비엘라 바이오, 인크. | Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법 |
-
2017
- 2017-03-09 MX MX2018010771A patent/MX2018010771A/es unknown
- 2017-03-09 BR BR112018067951A patent/BR112018067951A2/pt unknown
- 2017-03-09 AU AU2017231833A patent/AU2017231833B2/en active Active
- 2017-03-09 KR KR1020237034385A patent/KR102632796B1/ko active IP Right Grant
- 2017-03-09 SG SG11201807523PA patent/SG11201807523PA/en unknown
- 2017-03-09 WO PCT/US2017/021616 patent/WO2017156298A1/en active Application Filing
- 2017-03-09 CN CN201780029035.XA patent/CN109414499B/zh active Active
- 2017-03-09 KR KR1020247003436A patent/KR20240017421A/ko not_active Application Discontinuation
- 2017-03-09 CA CA3017197A patent/CA3017197A1/en active Pending
- 2017-03-09 CN CN202210535107.0A patent/CN114874322A/zh active Pending
- 2017-03-09 KR KR1020227029604A patent/KR102603010B1/ko active IP Right Grant
- 2017-03-09 KR KR1020187028675A patent/KR102439395B1/ko active IP Right Grant
- 2017-03-09 SG SG10202008769SA patent/SG10202008769SA/en unknown
- 2017-03-09 UA UAA201810089A patent/UA127731C2/uk unknown
- 2017-03-09 US US16/083,825 patent/US11072652B2/en active Active
- 2017-03-09 EP EP17764118.0A patent/EP3426298A4/en active Pending
- 2017-03-09 JP JP2018567013A patent/JP6979976B2/ja active Active
- 2017-03-09 RU RU2018135550A patent/RU2756109C2/ru active
- 2017-03-10 TW TW106107877A patent/TWI755380B/zh active
- 2017-03-29 AR ARP170100775A patent/AR109450A1/es unknown
-
2018
- 2018-09-06 MX MX2023010076A patent/MX2023010076A/es unknown
- 2018-09-06 IL IL261653A patent/IL261653A/en unknown
- 2018-10-04 ZA ZA2018/06597A patent/ZA201806597B/en unknown
-
2021
- 2021-05-28 AR ARP210101444A patent/AR122196A2/es unknown
- 2021-06-17 US US17/350,271 patent/US11673950B2/en active Active
- 2021-11-16 JP JP2021186637A patent/JP7354212B2/ja active Active
-
2023
- 2023-04-21 US US18/305,165 patent/US20230250167A1/en active Pending
- 2023-09-20 JP JP2023151943A patent/JP2024009808A/ja active Pending
-
2024
- 2024-06-03 AU AU2024203701A patent/AU2024203701A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018135550A (ru) | Связывающие ilt7 молекулы и способы их применения | |
| IL272572A (en) | Antibiotics to treat cancer | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| JP2014111644A5 (ru) | ||
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| JP2020536488A5 (ru) | ||
| RU2019116653A (ru) | Антитела к pd-1 и их применение | |
| CA3043763A1 (en) | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies | |
| JP2019516392A5 (ru) | ||
| JP2015535828A5 (ru) | ||
| JP2016505556A5 (ru) | ||
| JP2018121657A5 (ru) | ||
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| RU2016117053A (ru) | Нейтрализующие антитела к вирусу гриппа а и пути их применения | |
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| RU2010129558A (ru) | ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С АЛЬФА-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173 | |
| WO2009140348A4 (en) | Anti-il-6/il-6r antibodies and methods of use thereof | |
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| JP2019534892A5 (ru) | ||
| RU2012137380A (ru) | Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи | |
| JP2021500916A5 (ru) | ||
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа |